Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease

Molecular Psychiatry

Volumn 22, Issue 2, 2017, Pages 306-311

  Pascoal, T A ^a   Mathotaarachchi, S ^a   Mohades, S ^a   Benedet, A L ^a,b   Chung, C O ^a   Shin, M ^a   Wang, S ^a   Beaudry, T ^a   Kang, M S ^a   Soucy, J P ^c   Labbe, A ^d,e,f   Gauthier, S ^a   Rosa Neto, P ^a,c,e  

^a MCGILL UNIVERSITY   (Canada)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTERIOR CINGULATE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; CEREBROSPINAL FLUID; COGNITION; LONGITUDINAL STUDY; METABOLISM; PHYSIOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONGITUDINAL STUDIES; MALE; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 84961700362     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.37     Document Type: Article

References (46)

1. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
3. Jack CR Jr., Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014; 82: 1605-1612.
4. Knopman DS, Jack CR Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol 2013; 70: 1030-1038.
5. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014; 71: 1379-1385.
6. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957-965.
7. Knopman DS, Jack CR Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012; 78: 1576-1582.
8. Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-1791.
9. Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol 2011; 121: 145-147.
10. Trojanowski JQ. Tauists, Baptists, Syners, Apostates, and new data. Ann Neurol 2002; 52: 263-265.
11. Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sanchez-Saudinos MB, Sala I, et al. Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol 2014; 76: 223-230.
12. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, et al. Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011; 70: 657-661.
13. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, et al. Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 2012; 69: 709-713.
14. Ittner LM, Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
15. Chabrier MA, Cheng D, Castello NA, Green KN, LaFerla FM. Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. Neurobiol Dis 2014; 64: 107-117.
16. Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 2014; 17: 304-311.
17. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69: 871-877.
18. Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F] FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 2012; 39: 990-1000.
19. Dowling NM, Johnson SC, Gleason CE, Jagust WJ, Alzheimer's Disease Neuroimaging I. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. Neuroimage 2015; 105: 357-368.
20. Eskildsen SF, Coupe P, Fonov V, Manjon JV, Leung KK, Guizard N, et al. BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage 2012; 59: 2362-2373.
21. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999; 24: 521-529.
22. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60: 534-542.
23. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-397.
24. Quintanilla RA, von Bernhardi R, Godoy JA, Inestrosa NC, Johnson GV. Phosphorylated tau potentiates Abeta-induced mitochondrial damage in mature neurons. Neurobiol Dis 2014; 71: 260-269.
25. Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid-beta with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. J Alzheimer's Dis 2013; 36: 285-295.
26. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-7289.
27. Wang J, Yan K, Wu ZQ, Zheng CY, Xu RX, Chen LH, et al. TDP-43 interaction with the intracellular domain of amyloid precursor protein induces p53-associated apoptosis. Neurosci Lett. 2014; 569: 131-136.
28. Kuhl DE, Metter EJ, Riege WH, Hawkins RA. The effect of normal aging on patterns of local cerebral glucose utilization. Ann Neurol 1984; 15: S133-S137.
29. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 1996; 16: 385-398.
30. Lowe VJ, Weigand SD, Senjem ML, Vemuri P, Jordan L, Kantarci K, et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 2014; 82: 1959-1967.
31. Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009; 72: 513-520.
32. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
33. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-1165.
34. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
35. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014; 84: 608-622.
36. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 2013; 136 (Pt 5): 1383-1398.
37. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131(Pt 6): 1630-1645.
38. Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain 2015; 138(Pt 9): 2716-2731.
39. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
40. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; 45: 30-40.
41. Brandt R, Hundelt M, Shahani N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochimi Biophys Acta 2005; 1739: 331-354.
42. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain 2015; 138(Pt 3): 772-783.
43. Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer's Disease. J Alzheimers Dis 2015; 45: 1077-1088.
44. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015; 138: 2020-2033.
45. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012; 11: 1006-1012.
46. Jagust WJ, Landau SM, Alzheimer's Disease Neuroimaging I. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012; 32: 18227-18233.